**Text S1. List of contacts to obtain individual-level datasets for the 12 countries which undertook national TB prevalence surveys listed in this manuscript.**

This list is correct as of 21th August 2020 but as the national TB programme managers often change, please contact Irwin Law <lawir@who.int> or Katherine Floyd <floydk@who.int> for the latest contacts if required.

**Ethiopia**

Dr Lelisa Fekadu [Lefekadu1@gmail.com](mailto:Lefekadu1@gmail.com)

**Gambia**

Mr Adama Jallow [adamahaddyjatou@gmail.com](mailto:adamahaddyjatou@gmail.com)

**Ghana\***

Dr Frank Bonsu [fabonsu@gmail.com](mailto:fabonsu@gmail.com)

Dr Zeleke Alebachew zalebachew@gmail.com

**Kenya**

Dr Elizabeth Onyango [lizonyango2004@gmail.com](mailto:lizonyango2004@gmail.com)

The survey data is available as a supplementary file of their Plos One paper:

Enos M, Sitienei J, Ong’ang’o J, Mungai B, Kamene M, Wambugu J, et al. (2018) Kenya tuberculosis prevalence survey 2016: Challenges and opportunities of ending TB in Kenya. PLoS ONE 13(12): e0209098. <https://doi.org/10.1371/journal.pone.0209098> pmid:30586448

**Malawi\***

Dr James Mpunga [mpungajay@gmail.com](mailto:mpungajay@gmail.com)

**Nigeria**

Dr Adebola Lawanson [oluwadarasimi22@gmail.com](mailto:oluwadarasimi22@gmail.com)

**Rwanda**

Dr Patrick Migambi [Patrick.migambi@rbc.gov.rw](mailto:Patrick.migambi@rbc.gov.rw)

**Sudan**

Dr Mahmoud Eltayeb Eltahir [mah5oud@yahoo.com.au](mailto:mah5oud@yahoo.com.au)

**United Republic of Tanzania**

Dr Beatrice Mutayoba [beatricemutayoba@ntlp.go.tz](mailto:beatricemutayoba@ntlp.go.tz)

**Uganda**

Dr Stavia Turyahabwe [turyahabwestavia@gmail.com](mailto:turyahabwestavia@gmail.com)

**Zambia**

Dr Patrick Lungu [lungupatrick99@gmail.com](mailto:lungupatrick99@gmail.com)

**Zimbabwe\***

Dr Charles Sandy [csandy@healthnet.zw](mailto:csandy@healthnet.zw)

\*These data are available on request from Irwin Law <lawir@who.int>

**Text S2. Other screening criteria**

All surveys used a symptom questionnaire and chest X-ray to determine if a participant was screened positive and therefore eligible to submit sputum specimens. However, in some countries, *other* screening criteria were used.

**Gambia, Ghana, Kenya, Rwanda, Uganda and Zimbabwe**

Participants exempt from chest X-ray and symptom screen negative.

**Ethiopia**

Participants exempt from chest X-ray but with one of the following criteria were also requested to submit sputum specimens: weight loss ≥3 kg in the past month, night sweats ≥2 weeks, fever ≥2 weeks or contact with a TB patient in the past year.

**Sudan**

* Symptom-screen negative (or missing) and chest X-ray exempted (vast majority of other participants)
* Symptom-screen negative (or missing) and chest X-ray result missing
* Symptom-screen negative and chest X-ray negative but currently on TB treatment
* Off-site participants who were not interviewed or offered a chest X-ray due to various reasons e.g. immobility, and therefore sputum samples were directly collected from these participants.